Other languages Synairgen plc

Equities

SNG

GB00B0381Z20

Market Closed - London S.E. Other stock markets 16:35:08 28/06/2024 BST			5-day change	1st Jan Change
4.2 ^GBX	+9.66%		-24.87%	-29.71%

06-27	Synairgen slashes costs and focuses on small hospital trials	AN
06-27	Synairgen plc Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Synairgen slashes costs and focuses on small hospital trials	06-27
Synairgen plc Reports Earnings Results for the Full Year Ended December 31, 2023	06-27
AstraZeneca target raised; Antofagasta lowered	05-07
Synairgen names Phytome's Joseph Colliver as CFO	11/10/23
Biotech Company Synairgen Names New CFO	11/10/23
Synairgen plc Announces Board Changes	11/10/23
Synairgen promotes Marcin Mankowski to chief medical officer	03/10/23
Synairgen plc Announces Appointment of Dr. Marcin Mankowski as Chief Medical Officer	03/10/23
Synairgen narrows interim loss on reduced R&D spending	21/09/23
Synairgen plc Reports Earnings Results for the Half Year Ended June 30, 2023	21/09/23
Synairgen loss narrows; aims to develop SNG001	27/04/23
Synairgen plc Reports Earnings Results for the Full Year Ended December 31, 2022	27/04/23
Synairgen plc Announces the Online Publication of Data from Its Phase 3 Sprinter Trial in the Peer Reviewed European Respiratory Journal Open Research	23/12/22
Synairgen plc Appoints Amanda Radford FCA to the Board as an Independent Non-Executive Director and Chair of the Audit Committee	01/12/22
Synairgen Unveils Promising Phase Two Trial Results for Investigational Treatment Against COVID-19	04/10/22
Synairgen plc Announces Topline Data for Participants Treated with Sng001 in the Us National Institutes of Health/ Aids Clinical Trials Group-Led Activ-2 Phase 2 Adaptive Platform Trial for Covid-19	04/10/22
Synairgen plc Announces Changes to Its Board	29/09/22
Synairgen plc Reports Earnings Results for the Half Year Ended June 30, 2022	29/09/22
Synairgen plc to Present 60 and 90-Day Long COVID Data from Phase 3 SPRINTER Study in Hospitalised COVID-19 Patients at IDWeek 2022	20/09/22
Synairgen's SNG001 Reduces Long COVID-19 Symptoms In Follow-up Visits After Late-stage Trial	20/09/22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Synairgen plc

Equities

SNG

GB00B0381Z20

Other languages

Filters